JP Morgan Maintains Overweight on Conmed, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus maintains an Overweight rating on Conmed (NYSE:CNMD) and raises the price target from $125 to $145.
July 27, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Conmed and raises the price target from $125 to $145, indicating a positive outlook for the stock.
The raised price target by JP Morgan indicates a positive outlook for Conmed. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100